$BMY

Bristol Myers Squibb surges 5% after beating Q1 earnings expectations, with growth portfolio sales up 12% and full-year guidance reaffirmed.

Bristol-Myers Squibb stock jumped 4.44% after Q1 earnings beat expectations, with revenue up 3% and growth portfolio surging 12% year-over-year.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

Sun Pharma agrees to acquire Organon for $14/share in all-cash deal, sending shares up 16.87% as women's health firm finds exit after struggling 2021 Merck spinoff.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

PTCL market valued at USD 800 million in 2025 to grow 7% annually through 2036, driven by emerging therapies and rising disease incidence. U.S. represents 68% of market.

Biotech M&A surges as $300B patent cliff looms by 2030. Three gene-editing firms positioned as acquisition targets offer varying risk profiles.

Global vulvar cancer market expected to expand through 2035, driven by aging populations and HPV prevalence. Merck, Bristol Myers Squibb, and AstraZeneca lead innovation in immunotherapies despite reimbursement headwinds.

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Targeted alpha therapy market surging with 30+ drugs in clinical trials. Major pharma M&A signals confidence in precision oncology's future.

Global oncolytic virus immunotherapy market projected to exceed $5 billion by 2031, driven by three approved therapies and 150+ clinical candidates advancing combination approaches.

Alpha thalassemia market poised for significant expansion driven by rising prevalence, diagnostic advances, and pipeline therapies from $AGIOS and $NVO through 2036.

Bristol Myers Squibb trades at attractive 9.5x forward P/E with 4.2% yield and 17 years of dividend hikes, but faces revenue declines and patent expiration risks.

CVS Health and Bristol Myers Squibb present recession-resistant dividend opportunities, trading at attractive valuations with yields of 3.37% and 4.20% respectively.

SLE drug market projected to grow nearly 150% to $5.9B by 2034 on new therapies, but biosimilar competition and pricing pressure could limit upside.

Oxford BioTherapeutics partners with Bristol Myers Squibb to develop T-cell engager therapies for solid tumors, marking third major pharma deal in a year.

Interstitial lung disease market valued at $6B in 2025 expected to grow 8.7% annually through 2036, driven by FDA-approved therapies and emerging pipeline candidates.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Global bile duct cancer market projected to reach $3.89B by 2030 from $2.59B in 2025, driven by immunotherapy, AI diagnostics, and rising disease prevalence.

Esophageal cancer market projected to grow 44% to $2.37B by 2030 at 9.5% CAGR, with Pfizer, Roche, and Merck dominating through precision oncology and immunotherapy innovations.